Trial Profile
A study evaluating efficacy of [18F]fluorothymidine- identified active bone marrow sparing for pelvic cancer patients treated with chemoradiation therapy.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 Jul 2017
Price :
$35
*
At a glance
- Drugs F-18 fluorothymidine (Primary)
- Indications Pelvic cancer
- Focus Diagnostic use
- 26 Jul 2017 New trial record